Pros and Cons of Genus plc in the next few years
Pros
?
S********** s********
?
B****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | 0.000% | 2.400% | -4.478% | -12.925% | -12.925% | -6.637% | -60.310% |
| Ligand Pharmaceuticals | 0.000% | -3.053% | -9.286% | 120.870% | 53.012% | 316.393% | 164.970% |
| United Therapeutics | -0.090% | -3.340% | -7.866% | 76.129% | 4.985% | 111.804% | 193.203% |
| Ionis Pharmaceuticals Inc. | 0.870% | -3.859% | -33.790% | 27.258% | -30.341% | 31.463% | 48.634% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat

